Drug Profile
Recombinant staphylokinase - Supergene
Alternative Names: Fortelyzin; Forteplase®; Gene modified staphylokinase - Supergene; Recombinant nonimmunogenic staphylokinase - Supergene; Recombinant staphylokinase variant - SupergeneLatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Supergene
- Class Anti-ischaemics; Metalloendopeptidases; Plasminogen activator enzymes; Recombinant proteins; Thrombolytics; Vascular disorder therapies
- Mechanism of Action Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Peripheral arterial occlusive disorders; Pulmonary embolism; Stroke
- Phase II/III COVID 2019 infections
- No development reported Myocardial infarction
Most Recent Events
- 12 Apr 2024 Supergene plans the FORPE-2 phase III trial for Pulmonary embolism in Russia (IV, Injection) in May 2024 (NCT06362746)
- 29 Jun 2023 Supergene completes a phase III trial in Pulmonary embolism in Russia (IV) (NCT04688320)
- 31 May 2023 Supergene terminates the phase II/III FORRIF trial for COVID-2019 infections in Russia (Inhalation) due to no patients (NCT05135546)